Search Result

Results for "

Cell+cytotoxicity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Akt (3) Antibiotic (1) Apoptosis (5) Bacterial (3) Bcl-2 Family (1) CD276/B7-H3 (1) CD3 (1) CD74 (1) CGRP Receptor (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (2) EGFR (1) Endothelin Receptor (2) Eukaryotic Initiation Factor (eIF) (1) HIV (2) IFNAR (1) IKK (1) Interleukin Related (2) JNK (1) LILRB (1) MMP (3) Mucin (1) NF-κB (2) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (2) Pregnane X Receptor (PXR) (1) PROTACs (1) Proteasome (1) Reactive Oxygen Species (ROS) (1) Sec61 (1) STAT (1) TNF Receptor (2)
By Research Areas:	Cancer (24) Infection (5) Inflammation/Immunology (2) Neurological Disease (2)

By Targets:

17β-HSD (1)

Akt (3)

Antibiotic (1)

Apoptosis (5)

Bacterial (3)

Bcl-2 Family (1)

CD276/B7-H3 (1)

CD3 (1)

CD74 (1)

CGRP Receptor (1)

Cholinesterase (ChE) (1)

DNA/RNA Synthesis (2)

EGFR (1)

Endothelin Receptor (2)

Eukaryotic Initiation Factor (eIF) (1)

HIV (2)

IFNAR (1)

IKK (1)

Interleukin Related (2)

JNK (1)

LILRB (1)

MMP (3)

Mucin (1)

NF-κB (2)

PD-1/PD-L1 (2)

Phosphodiesterase (PDE) (2)

Pregnane X Receptor (PXR) (1)

PROTACs (1)

Proteasome (1)

Reactive Oxygen Species (ROS) (1)

Sec61 (1)

STAT (1)

TNF Receptor (2)

By Research Areas:

Cancer (24)

Infection (5)

Inflammation/Immunology (2)

Neurological Disease (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13259C

(R)-MG-132 15+ Cited Publications (S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al	Proteasome	Cancer
(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132 .

HY-P99634

Gatipotuzumab PankoMab; DS-3939a antibody	Mucin	Cancer
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .

HY-P991155

Ramantamig JNJ-79635322; JNJ-5322	CD3 TNF Receptor	Cancer
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .

HY-Y0493

HODHBt HOOBt	STAT HIV	Infection Cancer
HODHBt (HOOBt) inhibits STAT5-SUMO interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .

HY-P9996

Reozalimab LY3434172; IBI-318	PD-1/PD-L1	Cancer
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .

HY-139615

Sec61-IN-1	Sec61	Cancer
Sec61-IN-1 (compound A317) is a potent sec61 inhibitor that effectively targets glioma cells and enhances T cell cytotoxic effects[1][2].

HY-W028690

DNMDP 4 Publications Verification	Phosphodiesterase (PDE)	Cancer
DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity .

HY-121300

Kendomycin (-)-TAN2162	Antibiotic Bacterial Endothelin Receptor CGRP Receptor	Infection Cancer
Kendomycin ((−)-TAN 2162) is a polyketide antibiotic with remarkable antibacterial and cancer cells cytotoxic activities. Kendomycin tends to be bacteriostatic rather than bactericidal and inhibits the growth of the methicillin-resistant Staphylococcus aureus (MRSA) strain COL at a low concentration (MIC of 5 μg/mL). Kendomycin is a potent antagonist of the endothelin receptor and a calcitonin receptor agonist which plays its role as an anti-osteoporotic agent .

HY-107101

(5R)-5-Hydroxytriptolide PG 701; LLDT-8; 5α-Hydroxytriptolide	IFNAR CD74 JNK Interleukin Related TNF Receptor NF-κB HIV	Inflammation/Immunology
(5R)-5-Hydroxytriptolide is an extracted compound from Tripterygium, and shows lower cell cytotoxicity and higher immunosuppressive activity. (5R)-5-Hydroxytriptolide can be used for study of rheumatoid arthritis .

HY-122751

(R)-DNMDP	Phosphodiesterase (PDE)	Cancer
(R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC₅₀ compared to the (S)-enantiomer in HeLa cell line .

HY-N15414

Demethoxykanugin Desmethoxykanugin	Cholinesterase (ChE)	Neurological Disease Cancer
Demethoxykanugin (Desmethoxykanugin, compound 1) is a acetylcholine (AChE) inhibitor. Demethoxykanugin shows cell cytotoxicity agains Vero cells .

HY-P990719

Efbalropendekin alfa XmAb24306	Interleukin Related	Inflammation/Immunology Cancer
Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .

HY-P991092

IBI-334	EGFR CD276/B7-H3	Cancer
IBI-334 is a bispecific B7-H3 and EGFR antibody. IBI-334 has an EGFR arm for signal blockage and is coupled with a fine-tuned B7-H3 arm with optimal affinity and binding domain. IBI-334 shows antibody-mediated cell cytotoxicity (ADCC) effects. IBI-334 has a wide range of applications in many EGFR-driven solid tumors .

HY-155067

Antitubercular agent-38	Bacterial	Infection
Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .

HY-N1324

Sanggenon N	Others	Others
Sanggenon N is an isoprenylated flavonoid that can be isolated from the root bark of Morus alba.Sanggenon N has hepatoprotective activities on t-BHP-induced cell cytotoxicity in HepG2 cells with an EC₅₀ of 23.45 μM .

HY-158019

Anticancer agent 196	DNA/RNA Synthesis	Cancer
Anticancer agent 196 (compound 1) shows cell cytotoxicity with IC₅₀ values of 7.69 µM and 54.2 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 196 can induce DNA damage .

HY-158020

Anticancer agent 197	DNA/RNA Synthesis	Cancer
Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC₅₀ values of 10.03 µM and 73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage .

HY-147871

Antimycobacterial agent-3	Bacterial	Infection
Antimycobacterial agent-3 (Compound 1h) is an antimycobacterial agent against both agent-sensitive MTB strain H37Rv and drug-resistant clinical isolates (MIC: < 0.029–0.110 μM). Antimycobacterial agent-3 shows low cell cytotoxicity .

HY-157935

17β-HSD10-IN-3	17β-HSD	Neurological Disease
17β-HSD10-IN-3 (compound 23) is a 17β-HSD10 inhibitor with the IC₅₀ of 5.59 μM. 17β-HSD10-IN-3 shows no cell cytotoxicity toward the HEK-293 cell line up to 20 μM .

HY-146218

MMP-9-IN-5	MMP Akt Apoptosis	Cancer
MMP-9-IN-5 is a MMP-9 inhibitor (IC₅₀: 4.49 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-5 also inhibits _AKT activity (IC₅₀: 1.34 nM). MMP-9-IN-5 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-5 can be used in the research of cancers .

HY-146216

MMP-9-IN-3	MMP Akt Apoptosis	Cancer
MMP-9-IN-3 is a MMP-9 inhibitor (IC₅₀: 5.56 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-3 also inhibits AKT activity (IC₅₀: 2.11 nM). MMP-9-IN-3 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-3 can be used in the research of cancers .

HY-146217

MMP-9-IN-4	MMP Akt Apoptosis	Cancer
MMP-9-IN-4 is a MMP-9 inhibitor (IC₅₀: 7.46 nM) that has H-π interactions with MMP-9. MMP-9-IN-4 also inhibits _AKT activity (IC₅₀: 8.82 nM). MMP-9-IN-4 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-4 can be used in the research of cancers .

HY-155337

eIF4E-IN-6	Eukaryotic Initiation Factor (eIF)	Cancer
eIF4E-IN-6(compound 4b) is a GMP analogs synthesized to targeteIF4Eand restrain its binding to cap mRNA.eIF4E-IN-6shows cell cytotoxicity against Caco-2, HepG-2,and MCF-7 cells, withIC₅₀values of 31, 27, and 21 μM, respectively .

HY-157940

Methylsolfonyl 25(S)-Δ7-dafachronic acid	Endothelin Receptor	Infection
Methylsolfonyl 25(S)-Δ7-dafachronic acid (compound 3) is a selective ssDAF-12 agonist with the IC₅₀ of 0.41 μM. Methylsolfonyl 25(S)-Δ7-dafachronic acid shows low cell cytotoxicity in HepG2 cells with IC₅₀ of >200 μM. Methylsolfonyl 25(S)-Δ7-dafachronic acid can be used for study of parasitism .

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion .

HY-169264

SJYHJ-026	PROTACs Pregnane X Receptor (PXR)	Cancer
SJYHJ-026 (compound 37) is a pregnane X receptor (PXR) PROTAC degrader with the DC₅₀ of 86.6 nM and maximal degradation of 66.4%. SJYHJ-026 shows cell cytotoxic aganist SNU-C4 HiBiT-PXR KI cells with the IC₅₀ values of 97.4 μM (24 h) and 99.5 μM (72 h) (Blue: VHL ligand HY-125845,Black: linker HY-43048；Pink: PXR inhibitor HY-169277) .

HY-P991935

ANT1034	Apoptosis	Cancer
ANT1034 is humanized anti-CD52 antibody. ANT1034 directs antibody dependent and complement dependent cell cytotoxicity, induces Apoptosis when cross-linked or in the presence of a cross-linking antibody. ANT1034 leads to increased survival in a SCID CD52 tumour xenograft model. ANT1034 can be used for the research of B cell malignancies .

HY-P992389

IO-202	LILRB	Cancer
IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors .

HY-181837

IKKβ-IN-7	IKK NF-κB Bcl-2 Family Reactive Oxygen Species (ROS) Apoptosis	Cancer
IKKβ-IN-7 is an IKKβ inhibitor with an IC₅₀ value of 9.44 μM. IKKβ-IN-7 induces DNA damage, S-phase cell cycle arrest, ROS accumulation, mitochondrial membrane potential loss, and apoptosis. IKKβ-IN-7 inhibits phosphorylation of p65 and IκBα, suppresses p65 nuclear translocation, and regulates NF-κB-controlled genes. IKKβ-IN-7 suppresses tumor growth in xenograft models and shows activity against colorectal cancer with low normal cell cytotoxicity. IKKβ-IN-7 can be used for the research of colorectal cancer .

Cat. No.	Product Name	Target	Research Area	Image